Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: Revisiting gene delivery to the brain: silencing and editing
João
Conniot
ab,
Sepehr
Talebian
cd,
Susana
Simões
e,
Lino
Ferreira
*ef and
João
Conde
*ab
aNOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal. E-mail: joao.conde@nms.unl.pt
bCentre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal
cIntelligent Polymer Research Institute, ARC Centre of Excellence for Electromaterials Science, AIIM Facility, University of Wollongong, NSW 2522, Australia
dIllawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW 2522, Australia
eCNC – Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal. E-mail: lino@uc-biotech.pt
fFaculty of Medicine, University of Coimbra, 3030-789 Coimbra, Portugal
First published on 6th January 2021
Abstract
Correction for ‘Revisiting gene delivery to the brain: silencing and editing’ by João Conniot et al., Biomater. Sci., 2021, DOI: 10.1039/D0BM01278C.
The authors regret the incorrect version of Fig. 2 was included in the original manuscript. The correct version of Fig. 2 is as shown below, where ref. 188, 189, 190, 138 and 177 from the original article, are shown as ref. 1–5, respectively.
 | ||
| Fig. 2 Viral and non-viral delivery for gene silencing in brain, (A) AAV-mediated SOD1 silencing by overexpression of miRNA against human SOD1 coding sequence, to prevent motoneuron degeneration caused by SOD1 mutation. Reproduced with permission.1 Copyright 2015, Wiley. (B) Lentivirus-mediated miRNA-guided neuron tag (“mAGNET”) to restrict transgene expression to cortical inhibitory (GABA+) neurons in the mouse neocortex (GABA mAGNET). Reproduced with permission.2 Copyright 2018, Elsevier. (C) RNAi therapy for human glioblastoma in vivo using siRNA-loaded nontoxic brain-targeting chimaeric polymersomes (ANG-CP-siRNA). Reproduced with permission.3 Copyright 2018, Elsevier. (D) A cyclic peptide iRGD (CCRGDKGPDC)-conjugated solid lipid nanoparticle (SLN) to deliver small interfering RNAs (siRNAs) against both epidermal growth factor receptor (EGFR) and PD-L1 for combined targeted and immunotherapy against glioblastoma. Reproduced with permission.4 Copyright 2019, American Chemical Society. (E) Targeted delivery of theranostic polyfunctional gold–iron oxide nanoparticle (polyGION) surface loaded with therapeutic miRNAs (miR-100 and antimiR-21) to glioblastoma in mice. Reproduced with permission.5 Copyright 2019, Elsevier. | ||
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
References
- E. Dirren, J. Aebischer, C. Rochat, C. Towne, B. L. Schneider and P. Aebischer, Ann. Clin. Transl. Neurol., 2015, 2, 167–184 CrossRef CAS.
- M. K. Keaveney, H.-a. Tseng, T. L. Ta, H. J. Gritton, H.-Y. Man and X. Han, Cell Rep., 2018, 24, 294–303 CrossRef CAS.
- Y. Shi, Y. Jiang, J. Cao, W. Yang, J. Zhang, F. Meng and Z. Zhong, J. Controlled Release, 2018, 292, 163–171 CrossRef CAS.
- G. Erel-Akbaba, L. A. Carvalho, T. Tian, M. Zinter, H. Akbaba, P. J. Obeid, E. A. Chiocca, R. Weissleder, A. G. Kantarci and B. A. Tannous, ACS Nano, 2019, 13, 4028–4040 CrossRef CAS.
- U. K. Sukumar, R. J. C. Bose, M. Malhotra, H. A. Babikir, R. Afjei, E. Robinson, Y. Zeng, E. Chang, F. Habte, R. Sinclair, S. S. Gambhir, T. F. Massoud and R. Paulmurugan, Biomaterials, 2019, 218, 119342 CrossRef CAS.
| This journal is © The Royal Society of Chemistry 2021 |